BJH - volume 6, issue 2, may 2015
M. Oyaert MSc, M. Delforge MD, PhD, N. Boeckx MD, PhD
Flow cytometric immunophenotyping is recommended for diagnosis, classification and monitoring of disease in monoclonal gammopathies. Furthermore, it is a useful diagnostic tool for clinical practice and has various applications, such as its ability to distinguish between normal, reactive and malignant plasma cells, to evaluate the risk of progression from monoclonal gammopathy of undetermined significance to plasma cell myeloma, to provide prognostic information, to evaluate the presence of minimal residual disease and to identify new therapeutic targets. The incorporation of novel therapies in the management of patients diagnosed with plasma cell neoplasms has increased depth and frequency of response, as well as prolonged progression free and overall survival. Along with these improvements in therapeutic strategies, definition of responses to treatment has evolved over time. It was therefore necessary to develop reproducible and sensitive assays for detection and monitoring of minimal residual disease and to define its prognostic value in predicting progression free and overall survival, to allow for consolidation and maintenance therapeutic strategies and to evaluate the efficacy of novel therapies.
(BELG J HEMATOL 2015;6(2):46–53)
Read moreBJH - volume 5, issue Abstract Book BHS, january 2014
M. Mukovnikova , N. Boeckx MD, PhD, T. Devos MD, PhD
BJH - volume 5, issue Abstract Book BHS, january 2014
E. Del Biondo MD, P. Vandenberghe MD, PhD, B. Dewaele PhD, A. Kochuyt , N. Boeckx MD, PhD
BJH - volume 5, issue Abstract Book BHS, january 2014
C. Van Laer PharmD, J. De Roover , B. Wilmsen , N. Boeckx MD, PhD
BJH - volume 5, issue Abstract Book BHS, january 2014
V. Roobrouck , S. Chakraborty , T. Vanwelden , K. Sels , E. Lazarri , S. Pandey , N. Boeckx MD, PhD, M. Delforge MD, PhD, C. Verfaillie
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
